News
Trial signals major milestone in hunt for new TB drugs
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks...
News
Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis
Roche announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint. After 24 weeks of treatment, RA patients who received...
News
Novartis begins shipment of Fluvirin influenza seasonal vaccine in US
Novartis has commenced shipment of Fluvirin influenza vaccine for the 2012-2013 influenza season, in the US. Novartis plans to ship more than 30 million doses of the Fluvirin vaccine which has been reformulated to include two...
News
GSK wins FDA priority review for Promacta supplemental new drug application
GlaxoSmithKline, Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. Eltrombopag, known by the...
News
Catalent begins supply of Abilify antipsychotic drug to Otsuka Pharma
Catalent has started supplying its antipsychotic drug, Abilify, an orally disintegrating tablet (ODT) to Otsuka Pharmaceutical. Abilify ODT, which utilizes Catalent's Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated...
News
Bloodstream scavenger inhibits clotting without increased bleeding
A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges - stopping the formation of blood clots...
News
Novartis gains FDA approval for Afinitor® in advanced breast cancerNovartis gains FDA approval for Afinitor® in advanced breast cancer
The US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets* (approval represents the first major advance for US patients with advanced HR+ breast cancer since aromatase inhibitors were introduced more than 15 years ago) for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read